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Background: Dysnatremia is a frequent finding in patients with community acquired pneu-
monia (CAP) and a predictor of mortality. We studied the relation between dysnatremia, co-
morbidities and CT-pro-AVP and MR-proANP.
Methods: We enrolled 2138 patients (60  18 years, 55% male) with CAP from the CAPNETZ
database. Pro-atrial natriuretic peptide (proANP), pro-vasopressin (proAVP), serum sodiumANP, atrial natriuretic peptide; ADH, antidiuretic hormone; AUC, area under the curve; AVP, arginin
pneumonia; CRP, C-reactive protein; ET-1, endothelin-1; ICD, international classification of diseases;
itonin; PSI, pneumonia severity index; ROC, receiver operating curve; WBC, white blood cells.
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Dysnatremia and mortality in CAP 1697and CRB-65 score were determined on admission. Patients were followed up for 28 days.
Sodium concentration on admission was examined as a function of mortality at 28 days. Hy-
ponatremia (HypoN) was defined as admission serum sodium <136 mmol/L, hypernatremia
(HyperN) as admission serum sodium >145 mmol/L.
Results: HypoN was diagnosed in 680 (31.8%) patients, HyperN in 29 (1.4%) patients. Comor-
bidities were associated with sodium levels, and CT-pro-AVP and MR-proANP were inversely
related to sodium levels. Patients with HypoN were older, had a higher CRB-65 score and
higher values of CT-proAVP and MR-proANP (all p < 0.05). When examined as a function of
sodium values, a U-shaped association was found between sodium levels and 28 day mortal-
ity. In multivariate Cox proportional hazards analysis, HypoN and HyperN were independent
predictors of 28 day mortality. Sodium levels added to the predictive potential of proAVP
and proANP.
Conclusion: HypoN is common at admission among CAP patients and is independently asso-
ciated with mortality. HyperN is rare at admission among CAP patients but is also indepen-
dently associated with mortality. The combination of sodium and CT-pro-AVP and MR-proANP
levels achieved the highest prediction of mortality.
ª 2014 Elsevier Ltd. All rights reserved.Introduction
Hyponatremia is the most common electrolyte imbalance
seen in clinical practice [1]. It is frequently present in
patients with community acquired pneumonia (CAP), but
also in other diseases like heart or liver failure [2e7].
The association between pneumonia and hyponatremia
was first described in 1962 [8]. The presence of
hyponatremia has been found to be associated with an
increase in mortality [9e11]. In fact, hyponatremia
<130 mmol/l is one of 20 parameters in the pneumonia
severity index (PSI), with a high relative weight [11]. On
the other hand, hypernatremia is also associated with
increased mortality, especially in ICU patients. However,
there are almost no data about the prevalence of hyper-
natremia and its influence on mortality in patients with
CAP.
There have been some smaller studies attempting to
determine the pathogenesis of hyponatremia in patients
with CAP. Hypovolemia and inappropriate secretion of
vasopressin have been suspected to be main factors for
hyponatremia to occur. From a pathophysiological point of
view, not only serum levels of vasopressin but also of
atrial natriuretic peptide should affect serum sodium
levels. However, the exact underlying mechanisms of
dysnatremia, particularly their relation to specific
comorbidities in patients with CAP remain uncertain.
The predictive power of dysnatremia for mortality,
particularly in combination with other novel biomarkers
such as vasopressin and atrial natriuretic peptide has not
been assessed. Moreover, with the development of aqua-
retic agents that may resolve hyponatremia, a better
understanding of the risks associated with hyponatriamia
is relevant [12e15]. Accordingly, we studied the
association among admission serum sodium,
comorbidities, CT-proAVP (arginine vasopressin), MR-
proANP (atrial natriuretic peptide) levels, and mortality
in patients with CAP based on data from the CAPNETZ
study.Materials and methods
Patients
CAPNETZ represents a German Competence network for the
studyofCAP (CAPNETZ,http://www.capnetz.de) [16].Within
CAPNETZ all new CAP-cases are reported via a network of
sentinel practices and hospitals to the study monitor of the
corresponding local clinical centre (LCC). Inclusion criteria
are: age18 years, a pulmonary infiltrate diagnosed by chest
X-ray, clinical symptoms consisting of cough or purulent
sputumorpositiveauscultation.Exclusioncriteriaareage<18
years, acquired or therapeutically induced immune defi-
ciency, florid tuberculosis or a possible nosocomial genesis of
infection (hospitalisation less than four weeks prior to infec-
tion). After inclusion in CAPNETZ all clinical parameters of the
patients are stored in an electronic database. Written
informed consent was obtained from every patient prior to
inclusion in the study. The study was approved by the local
ethical committee. The recruitment of patients for this CAP-
NETZ substudy was from 2005 to 2009.
Our study was not an intervention study with imple-
mentation of standardized criteria for the diagnosis and
therapy of CAP according to guidelines, biomarker levels or
CRB-65 score. CRB-65 score was determined in all patients.
The CRB-65 score consists of four variables: new onset of
confusion, respiratory rate 30/min, blood pressure sys-
tolic <90 mmHg or diastolic 60 mmHg, age 65 years
[17,18]. One point is given for each parameter present
which results in CRB-65 scores 0e4.
The microbiological work-up for CAPNETZ patients has
been previously described [16]. Briefly it included respiratory
tract samples with Gram stain and culture, blood cultures,
blood samples for serological testing for Chlamydophila
pneumoniae andMycoplasmapneumoniae and a urine sample
for the detection of Legionella pneumophila serogroup 1 and
Streptococcus pneumoniae. Detection of respiratory patho-
gens was performed according to standard methods and
established microbiological guidelines [19].
1698 S. Kru¨ger et al.All patients were assessed at first presentation and during
follow-up according to a standardized data sheet. After 14
days all patients or relatives were contacted either person-
ally or via telephone for a structured interview on outcome
parameters including death. To assess the pneumonia
related number of deaths within 28 days and 180 days this
interview was repeated for all patients after 180 days.
Mortality was defined as death within the first 28 days.
Laboratory measurements
Venous blood samples were collected at the time of inclu-
sion into the study and as soon as possible after the diag-
nosis of CAP. Serum sodium was measured in a standard
fashion. Serum C-reactive protein (CRP) was measured by
nephelometry with a commercially available assay (Behring
Diagnostics, Marburg, Germany). Serum procalcitonin (PCT)
was determined by an immunofluorescent assay
(B.R.A.H.M.S PCT sensitive KRYPTOR, B.R.A.H.M.S AG,
Henningsdorf, Germany).
Because of the low half life of ANP and AVP as well as
instability and platelet binding of AVP, precursor fragments
of both hormones midregional Pro-Atrial Natriuretic Peptide
(MR-proANP) and C-terminal Pro-Vasopressin (CT-proAVP)
were analysed as alternative diagnostic targets. MR-proANP
and CT-proAVP levels directly reflect the release of their
rapidly degraded active hormones ANP and AVP [20e23].
MR-proANP measurements were performed using an
automated routine assay (BRAHMS MR-proANP KRYPTOR,
BRAHMS GmbH, Hennigsdorf, Germany) as described in
detail elsewhere [20,23]. CT-proAVP measurements were
performed with a sandwich immunoluminometric assay, as
described elsewhere except that the capture antibody was
replaced by a murine monoclonal antibody, leading to a
higher sensitivity (<0.4 pmol/L) [21]. Laboratory mea-
surements were performed in a blinded fashion without
knowledge of clinical parameters and microbiological re-
sults. Measurements of PCT, CT-proAVP and MR-proANP
were performed in one central laboratory.
Definition of dysnatremia
Hyponatremia was defined as an admission serum sodium
level <136 mmol/L, severe hyponatremia was defined as
serum sodium level <130 mmol/L. Hypernatremia was
defined as an admission serum sodium level >145 mmol/L,
severe hypernatremia was defined as serum sodium level
>150 mmol/L.
Statistics
Group comparisons of continuous variables were performed
using students t-test,ANOVAmodels orKruskaleWallis test, as
appropriate. Biomarker data were log-transformed. For Cox
regression analysis, sodium was also transformed using
restricted cubic splines to account for the U-shape relation-
ship between marker and hazard. Categorical data were
compared using Fisher’s Exact test or the c2-test with simu-
lated p-values using 2000 replicates, as appropriate. Cox
proportional-hazards regression was used to analyze the ef-
fect of several risk factors on short- and long-term survival inuni- and multivariable analyses. Models were compared using
the overall LR c2 statistic and p-value and the C index which
gives an equivalent to the AUC adopted for censored data.
Time-dependent ROC curves and time-dependent AUC values
are determined from censored survival data using the
KaplaneMeier method. Two univariate models including fac-
tors A and B, respectively, are compared using the LR (likeli-
hood ratio)c2 test for nestedmodels. The test statistic for the
test of addingA toB is calculated as thedifference of the LRc2
of the combined model A þ B and the LR c2 of the model
including only B. This is approximately c2-distributed with df
given as the difference between the df of model A þ B and
model B. Vice versa, a test of adding B to A is performed. If A
adds significantly to B, but B does not add to A, then it can be
concluded that A is significantly better at predicting outcome
than B. All statistical tests were 2-tailed and a p-value <0.05
was considered statistically significant. For multivariable
models, a bootstrap corrected version of the C index is given.
All statistical analyses were performed using R version 2.5.1,
especially libraries Hmisc and Design (http://www.r-project.
org) and Statistical Package for the Social Sciences (SPSS)
version 16.0 (SPSS Inc., Chicago, Illinois, USA).
Results
Patients
Baseline characteristics of the study population are sum-
marized in Table 1. In n Z 2138 patients mean age was
59.9  18.2 years. Overall, nZ 1448 patients (67.7%) were
hospitalised, n Z 690 (32.3%) were outpatients. The caus-
ative pathogen was identified in n Z 412 patients (19.3%)
[typical bacterial infection: n Z 145 (6.8%), atypical bac-
terial infection nZ 205 (9.6%), viral infection nZ 22 (1%),
mixed infections with two or more pathogens n Z 40
(1.9%)]. Overall, n Z 555 (26%) patients had antimicrobial
pre-treatment, 1538 had no antimicrobial pre-treatment.
Most patients had mild (CRB-65 Z 0) to moderate (CRB-
65 Z 1 and 2) severity of pneumonia at admission.
Prediction of severity
CT-proAVP and MP-proANP levels increased with increasing
CRB-65 scores, whereas there was no such increase in so-
dium levels (Fig. 1).
Dysnatremia
Hypernatremia was present in n Z 19 (1.3%) patients.
Hyponatremia was present in n Z 680 (31.8%) of patients.
Hyponatremia was generally mild, only n Z 117 (5.5%)
patients had serum sodium < 130 mmol/l. The association
of clinical parameters with hyponatremia is shown in Table
1. Patients with hyponatremia were older, had more
frequently congestive heart failure, chronic renal disease,
diabetes mellitus and malignancies, had a higher heart rate
and temperature, were more often acutely confused and
more often hospitalized.
Moreover, serum levels of CRP, WBC, urea, glucose, MR-
proANPand CT-proAVPon admissionwere significantly higher,
Table 1 Baseline characteristics of patients with and without hyponatremia (sodium < 136 mmol/L).
Characteristic No hyponatremia (n Z 1458) Hyponatremia (n Z 680) p-value*
Age years (SD) 58.5 (18.2) 62.71 (17.9) <0.0001
Male sex n (%) 850 (58.3) 375 (55.1) 0.16642
Smoker n (%) 200 (29.9) 426 (29.6) 0.95952
Comorbidities n (%)
Congestive heart failure 214 (14.7) 131 (19.4) 0.009
COPD 560 (38.5) 232 (34.2) 0.060
Chronic renal disease 93 (6.4) 71 (10.5) 0.002
Chronic liver disease 42 (2.9) 28 (4.1) 0.143
Cerebrovascular disease 118 (8.1) 57 (8.4) 0.867
Malignancy 133 (9.2) 91 (13.4) 0.002
Diabetes mellitus 204 (14) 150 (22.1) 0.0005
Physicaleexamination
Heart rate bpm (SD) 87.9 (18.0) 93.0 (18.4) <0.0001
Temperature C (SD) 37.5 (1.1) 38.1 (1.2) <0.0001
Confusion n (%) 99 (6.8) 68 (10) 0.01649
Respiratory rate 1/min (SD) 20.7 (6.2) 21.4 (5.8) 0.01440
Blood pressure
systolic mean mm Hg (SD) 130.9 (22.5) 130.3 (22.6) 0.57810
diastolic mean mm Hg (SD) 76.9 (12.1) 74.3 (13.4) <0.0001
Prior antibiotics n (%) 155 (22.9) 400 (27.5) 0.0267
Hospitalisation n (%) 881 (61.3) 567 (84.1) 0.0005
Aetiology of CAP n (%) 0.91604
Typical bact. pathogensa 97 (6.7) 48 (7.1)
Atypical pathogensb 140 (9.6) 65 (9.6)
Virusesc 13 (0.9) 9 (1.3)
Mixedd 27 (1.9) 13 (1.9)
Unknown 1181 (81) 545 (80.1)
CRB-65 n (%) 0.0005
0 642 (44) 205 (30.1)
1 594 (40.7) 326 (47.9)
2 178 (12.2) 123 (18.1)
3 40 (2.7) 24 (3.5)
4 4 (0.3) 2 (0.3)
Laboratory values
Median (IQR)
CRP (mg/dl) 54 (15e136.45) 132.4 (39e238) <0.0001
WBC (G/L) 10.3 (7.7e13.9) 12.8 (9e17.7) <0.0001
Urea (mmol/L) 4.8 (3.5e6.7) 5.5 (3.7e8.3) 0.00030
Glucose (mmol/l) 5.83 (4.77e7.28) 6.89 (5.56e8.61) <0.0001
MR-proANP 79.5 (44.7e173.1) 116.9 (63.7e229.3) <0.0001
CT-proAVP 9.77 (4.67e19.15) 13.22 (6.96e22.03) <0.0001
28 day mortality n (%) 44 (3) 39 (5.7) 0.002
a S. pneumoniae (n Z 98), H. influenzae (n Z 12), E. coli (n Z 6), Enterobacter spp. (n Z 5), Pseudomonas aeruginosa (n Z 5), S.
aureus (n Z 4), Klebsiella pneumoniae (n Z 4), Pseudomonas spp (n Z 2), Moraxella catarrhalis (n Z 1), Pseudomonas paucimobilis
(n Z 1), Pseudomonas fluorescens (n Z 1), Morganella morganii (n Z 1), H. parainfluenzae (n Z 1), Enterococcus spp. (n Z 1),
Enterococcus faecium (n Z 1), Citrobacter spp (n Z 1).
b Mycoplasma pneumoniae (n Z 151), Legionella spp (n Z 53), Chlamydia pneumoniae (n Z 1).
c Influenza A (n Z 19), Enteroviren (n Z 2), RS-Viren (n Z 1).
d Infections with two or more pathogens including the following combinations: two or more typical bacteria (n Z 10), two or more
atypical bacteria (nZ 5), typical bacterial plus atypical bacterial infection (nZ 17), typical or atypical bacterial infection plus viruses
(n Z 8).
Dysnatremia and mortality in CAP 1699as were CT-proAVP levels (13.22 [6.96, 22.03] vs. 9.77 [4.67,
19.15] pmol/L, p< 0.001) and MR-proANP levels (116.9 [63.7,
229.3] vs. 79.5 [44.7, 173.1] pmol/L, p < 0.001).
There was a significant inverse correlation of CT-proAVP
levels (r Z 0.14, CI 0.18, 0.10; p < 0.001) and MR-
proANP levels (r Z 0.17,CI 0.2, 0.14; p < 0.001) withsodium levels. CT-proAVP and MR-proANP levels increased
with increasing severity of CAP according to the CRB-65
score (p < 0.0001), whereas serum sodium levels
decreased with increasing severity of CAP (p < 0.0001).
In univariate Cox proportional-hazards regression anal-
ysis the following variables were significant predictors of
Figure 1 Admission levels of (A) sodium, (B) MR-proANP and (C) CT-proAVP in CAP patients according to CRB-65 score. Solid lines
denote median values, boxes represent 25th to 75th percentiles and whiskers indicate the range.
1700 S. Kru¨ger et al.hyponatremia (Table 2): age, respiratory rate, diastolic
blood pressure, heart rate, body temperature, glucose,
blood urea, WBC, CRP, PCT, CT-proAVP, and MR-proANP.
In multivariate Cox regression analysis adjusted for these
confounders the following variables were significant pre-
dictors of hyponatremia: diastolic blood pressure, glucose,
WBC, PCT, CT-proAVP, MR-proANP, CRP and body tempera-
ture. Accordingly, in multivariate Cox regression analysis the
following variables were significant predictors of severe
hyponatremia: CRP, PCT, CT-proAVP and MR-proANP.Dysnatremia, CT-proAVP, MR-proANP and
prediction of mortality
At 28 days follow-up, nZ 83 (3.9%) patients had died. Mean
sodium levels on admission were slightly lower (136 [132,139]
mmol/L) in nonsurvivors compared to levels in survivors
(137mmol/L [135,140], pZ 0.0355, Fig. 2). Differences were
clearly higher for CT-proAVP levels and MP-proANP levels
(Fig. 2, each p< 0.001). Themortality of patients with severe
hyponatremia<130 mmol/l was higher compared to patients
with only mild hyponatremia (9.9% vs. 5.7%). Hypernatremia
was also associatedwith a highermortality risk (Figs. 3 and 4).
The risk curve was U shaped with both low and high sodium
values representing high risk (Fig. 3).ROC curves illustrate the accuracy of CRB-65, CT-
proAVP, MR-proANP and plasma sodium to predict 28-days
mortality (Fig. 5). The AUC was highest for CT-proAVP
(0.82, 95% CI 0.78e0.86) and MR-proANP (0.80, 95% CI
0.76e0.84), which were comparable to the AUC for CRB-
65 (0.74). The AUC for plasma sodium (0.66) was signifi-
cantly lower compared to CT-proAVP, MR-proANP and CRB-
65.
In univariate analysis for 28 day mortality (Table 3) the
highest c2 values and C-indices were achieved of CRB-65
score, MR-proANP and CT-proAVP. In multivariate analysis
for 28d mortality, the highest c2 values and C-indices
resulted in the combined model of either CT-proAVP and
CRB-65 score or CT-proAVP and sodium.Discussion
The current study demonstrated that 1) hyponatremia
frequently occurred in patients with CAP, especially in
hospitalized patients, 2) sodium levels were associated
with distinct comorbidities and inversely correlated with
the serum concentrations of the vasoactive prohormones of
vasopressin and atrial natriuretic peptide, 3) hypona-
tremia, particularly severe hyponatremia, and hyper-
natremia were associated with higher 28 day mortality in
Table 2 Cox regression results for presence of hyponatremia, ranked by likelihood ratio c2 statistic.
Model n Events LR c2 d.f. p-value C index
Systolic blood pressure (mmHg) 2134 679 0.31 1 0.577 0.502
Sex 2138 680 1.88 1 0.17 0.516
Respiratory rate (1/min) 2130 679 5.89 1 0.015 0.548
Urea (mmol/L) 1929 608 8.06 1 0.0045 0.551
Diastolic blood pressure (mmHg) 2134 679 19.18 1 0.00001 0.561
Age (years) 2138 680 24.93 1 <0.00001 0.569
CT-proAVP (pmol/L) 2138 680 24.97 1 <0.00001 0.573
Heart rate (1/min) 2131 678 36.41 1 <0.00001 0.59
MR-proANP (pmol/L) 2134 678 49.84 1 <0.00001 0.606
Glucose (mmol/l) 2014 642 87.04 1 <0.00001 0.634
Leukocytes (G/L) 2103 669 87.78 1 <0.00001 0.626
Body temperature (C) 2113 675 110.65 1 <0.00001 0.639
C-reactive protein (mg/dl) 2117 674 116.05 1 <0.00001 0.657
Procalcitonin (ng/mL) 2134 678 116.4 1 <0.00001 0.661
Dysnatremia and mortality in CAP 1701CAP, and 4) hyponatremia added to the potential of CT-
proAVP and MR-proANP to predict mortality.
We found that hyponatremia was present in 31.8% of pa-
tients with CAP at presentation. This is quite similar to the
27.9% (of 342 patients) incidence previously reported [10]. InFigure 2 Admission levels of (A) sodium, (B) MR-proANP and (C) CT
Solid lines denote median values, boxes represent 25th to 75th pethat study, in most cases hyponatremia was only mild.
Nevertheless the presence of hyponatremia increased hospi-
tal length of stay by 2.3 days and was associated with a near
tripling of mortality in patients with hyponatremia, resulting
in a 7% increase in the risk of in-hospital mortality. In another-proAVP in CAP patients according to survival status at 28 days.
rcentiles and whiskers indicate the range.
Figure 3 Association between serum sodium concentration
(transformed by restricted cubic splines using 5 knots) and log
relative hazard (with 95% confidence interval) for mortality at
28 days.
Figure 5 Time-dependent ROC plots for survival outcome
after 28 days comparing CT-proAVP, MR-proANP, sodium and
CRB-65 score. Sodium spline-transformed using 4 knots to ac-
count for U-shape of risk association.
1702 S. Kru¨ger et al.retrospective analysis of an administrative database, hypo-
natremia was present only in 8.1% of CAP patients [9]. Hypo-
natremiawasassociatedwithahigherage,higher comorbidity
score, higher rates of ICU admission and length of hospital
stay.However, in contrast toour studyand to the studybyNair
etal., therewasnosignificantdifference inhospitalmortality.
This could be explained by the retrospective design based on
ICD codes and a less rigorous definition of CAP. FurthermoreFigure 4 Kaplan Meier analysis according to serum sodium
concentration (groups defined by deciles of sodium
concentration).patients with the ICD diagnosis of hyponatremia were
excluded at the risk of excluding patients with more severe
hyponatremia.
In our study, factors that were associated with hypona-
tremia included distinct comorbidities, higher severity of CAP
and higher inflammatory biomarkers, particularly elevated
levelsofCT-proAVPandMR-proANP. In fact,hyponatremiawas
significantly more frequently present in patients with chronic
heart failure, chronic renal disease, diabetes mellitus, and
malignancies, and also (althoughnon-significantly) in patients
with liver disease. However, the association of these comor-
bidities with sodium levels was weak and disappeared after
inclusion in a multivariate model.
The relationship of hyponatremia and higher pneumonia
severity probably reflects the presence of hypovolemia,
severe sepsis and subsequent activation of vasopressin and
MR-proANP. Two previous studies showed that patients with
pneumonia had a significant decrease in the ability to
reduce urine osmolality and excrete water loads [24,25]. In
these studies plasma vasopressin levels were significantly
increased during CAP compared to recovery, which was
explained by the phenomenon of resetting the vasopressin
osmostat. Another study could demonstrate that 68% of
patients with hyponatremia in CAP had characteristics
typical of the syndrome of inappropriate antidiuretic hor-
mone (ADH) secretion [26].
The increased mortality in patients with CAP and hypona-
tremia could be explained by the finding that hyponatremia is
correlatedwith higher pneumonia severity. The association of
hyponatremia and mortality may be causative, but since
CAPNETZ is an observational study this cannot be proven with
ourdata. Inprevious studies,weevaluatedMR-proANPandCT-
proAVP compared to inflammatory biomarkers and CRB-65
score for the prediction of short-termand long-termmortality
from CAP [27e30]. MR-proANP and CT-proAVP were signifi-
cantly better predictors for 28-day and especially for 180-day
Table 3 Cox regression results for 28-day survival, ranked by likelihood ratio c2 statistic. Sodium was evaluated both log-
transformed and spline transformed, using restricted cubic splines using five knots.
Model n Events LR c2 d.f. p-value C index
Sodium (log10, mmol/L) 2138 83 2.5 1 0.11302 0.567
WBC (log10, g/L) 2103 79 12.4 1 0.00042 0.625
CRP (log10, mg/L) 2117 82 19.4 1 0.00001 0.623
Sodium (spline, mmol/L) 2138 83 40.3 4 <0.00001 0.641a
CRB-65 (class 0, 1, 2, 3, 4) 2138 83 69.9 4 <0.00001 0.728a
MR-proANP (log10, pmol/L) 2134 83 100.2 1 <0.00001 0.802
CT-proAVP (log10, pmol/L) 2138 83 117.3 1 <0.00001 0.818
MR-proANP (log10, pmol/L), CRB-65 (class 0, 1, 2, 3, 4) 2134 83 126.6 5 <0.00001 0.816
a
MR-proANP (log10, pmol/L), sodium (spline, mmol/L) 2134 83 135.2 5 <0.00001 0.817
a
CT-proAVP (log10, pmol/L), CRB-65 (class 0, 1, 2, 3, 4) 2138 83 144.5 5 <0.00001 0.830
a
CT-proAVP (log10, pmol/L), sodium (spline, mmol/L) 2138 83 147.2 5 <0.00001 0.829
a
a c index bootstrap corrected.
Dysnatremia and mortality in CAP 1703mortality than the CRB-65 score and the inflammatory
markers PCT, CRPandWBC [30]. In another study to follow,we
found that the newcardiovascular biomarkersMR-proANP,CT-
proAVP, CT-proET-1 (endothlin-1) and MR-proADM (adreno-
medullin) are strong predictors of 28-day and 180-day mor-
tality from CAP with the best performance for MR-proADM
[29]. Various mechanisms may explain these observations.
First, both markers are elevated in sepsis as one of the main
causes of death in the acute phase of CAP [20,22,31,32].
Second, CT-proAVP and MR-proANP are increased in patients
with cardiac failure. The elevation of these biomarkers in CAP
might be due to underlying pre-existing cardiac disease and/
or septic cardiomyopathy. We could demonstrate that CT-
proAVP and MR-proANP are independent of pre-existing diag-
nosis of chronic heart disease or heart failure. As a result, CAP
may aggravate underlying previously unknown cardiovascular
or renal disease due to acute inflammatory activation. How-
ever, elevations in MR-proANP and CT-proAVPmight also be in
part a result of renal failure related to severe CAP.
Although dysnatremia was only moderately predictive of
mortality, the predictive potential of CT-proAVP and MR-pro-
ANP was increased in combination with sodium levels. The
improvement was comparable to that of a combination with
the CRB-65 score. Thus, sodium levels cannot be used as an
independent predictive tool alone but may be at best placed
together with other parameters (such as in the PSI) or, alter-
natively, with biomarkers such as CT-proAVP andMR-pro-ANP.
Severe hyponatremia can result in various complications
such as cerebral edema as well as risk for seizures, acute
brain injury and death [2]. However, in line with other
studies we found that in most cases hyponatremia was only
mild to moderate and not of a magnitude that would cause
direct severe harm, although even milder forms of hypo-
natremia may result in clinical relevant symptoms.
In fact, hyponatremia has been described as a predictor
for mortality in various other diseases. Hyponatremia is a
common finding patients suffering from acutely decom-
pensated heart failure with an incidence from 20% to 25%
[2e6]. From large studies of sodium concentrations and
heart failure, it is known that hyponatremia is more com-
mon in severe heart failure [33e35]. Low serum sodium
levels have been repeatedly described as a predictor of
adverse short-term outcomes [4e6,35,36]. Hyponatremia isa predictor of hospital mortality in patients with heart
failure. A large cohort study of nearly 50,000 patients with
acutely decompensated heart failure showed a prevalence
of hyponatremia of 20% with a 20% increase in the risk of
hospital death for each 3 mmol/L decrease in serum sodium
concentration below 140 mmol/L [4].
In patients with severe liver disease and candidates for
liver transplantation hyponatremia was found to be an
important predictor of survival [7]. Interestingly, in these
patients with severe liver disease as well as in patients with
congestive heart failure the authors found a U-shaped as-
sociation between serum sodium level and mortality
[4,7,37,38]. This is in accordance with our finding of an U-
shaped association between serum sodium level and mor-
tality of CAP, i.e. an increased risk for mortality both in
patients with both hyponatremia and hypernatremia.
Thus, hyponatremia seems to reflect a uniform response
to severe heart, lung, liver and renal diseases that goes along
with significant cardiovascular adaptive mechanisms. Main
drivers seem to be elevated serum levels of vasopressin and
natriuretic peptides. Therefore, from a pathophysiological
point of view the same principles of treatment could be
helpful in all these above mentioned diseases that go along
with volume overload and hypotonic hyperhydration. Hypo-
natremia canbecorrectedby appropriate therapy.Up tonow
there are no studies if vasopressin receptor antagonists
significantly improve serum sodium levels in patients with
CAP with an influence on clinical outcome.
The present study has some limitations. The population
studied mainly consisted of patients with mild to moderate
CAP and consequently, mortality was low. However, the
impact of dysnatremia is expected to be even higher in
severe CAP. Measurement of sodium, MR-proANP and CT-
proAVP are potentially influenced by other factors such as
sex and age. The timing of biomarkers was not exactly
standardized. However, blood samples were taken as soon
as possible after inclusion into the study. Because of the
large scale and the design of the CAPNETZ study, kinetics of
sodium, MR-proANP and CT-proAVP have not been per-
formed. Hyponatremia might have been affected by fluid
resuscitation or other treatment related factors. Although
the whole study cohort of patients were not strictly
consecutively included, this should not have a relevant
1704 S. Kru¨ger et al.impact on the findings of the study, because it was an
observational study and not an interventional study design.
The current study was an amalgamation of datasets from
three former sub-studies on biomarkers in CAPNETZ
[28e30]. However, this should not have influenced the re-
sults in a significant way, because the CAPNETZ study is
observational and not interventional.
In conclusion, the mechanisms behind the development
of hyponatremia are at least in part the higher levels of CT-
proAVP and MR-proANP, but overall hyponatremia is not
explained neither by comorbidities nor by levels of CT-
proAVP and MR-proANP alone. Hyponatremia but also
hypernatremia are predictors of 28 day mortality from CAP.
Sodium levels increase the predictive potential for mor-
tality of both CT-proAVP and MR-proANP.
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